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Uric acid and the state of the intrarenal renin-angiotensin sys-
tem in humans.
Background. Experimental hyperuricemia is marked by an
activated intrarenal renin-angiotensin system (RAS). The renal
vascular response to exogenous angiotensin II (Ang II) provides
an indirect measure of intrarenal RAS activity. We tested the
hypothesis that the serum uric acid concentration predicts the
renal vascular response to Ang II.
Methods. A total of 249 subjects in high sodium balance had
the renal plasma flow (RPF) response to Ang II measured. Para-
aminohippuric acid (PAH) clearance was used to estimate RPF.
Multivariable regression analysis determined if the serum uric
acid concentration independently predicts the RPF response
to Ang II. Variables considered included age, gender, race,
body mass index (BMI), hypertension status, blood pressure,
basal RPF, creatinine clearance, serum insulin, serum glucose,
serum high-density lipoprotein (HDL), serum triglycerides, and
plasma renin activity (PRA).
Results. Uric acid concentration negatively correlated with
the RPF response to Ang II (r = −0.37, P < 0.001). In univari-
ate analysis, age, BMI, hypertension, triglycerides, and blood
pressure were negatively associated, and basal RPF, HDL, and
female gender were positively associated with the RPF response
to Ang II. In multivariable analysis, serum uric acid concentra-
tion independently predicted the RPF response to Ang II (b =
−5.3, P < 0.001).
Conclusion. Serum uric acid independently predicted
blunted renal vascular responsiveness to Ang II, consistent with
results from experimental hyperuricemia showing an activated
intrarenal RAS. This could be due to a direct effect of uric acid
or reflect a more fundamental renal process. These data may
have relevance to the association of uric acid with risk for hy-
pertension and nephropathy.
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Controversy exists regarding the relationship of uric
acid to hypertension and renal disease in humans [1, 2].
It is unclear whether an elevation in uric acid concen-
tration contributes to or simply reflects disturbed renal
physiology such as alterations in the renal vasculature [3]
or in the tubular handling of sodium [4]. Recent work in
experimental hyperuricemia suggests that uric acid might
have a pathogenetic role in hypertension and nephropa-
thy. The hyperuricemic rat develops hypertension [5],
and the kidney of the hyperuricemic rat develops affer-
ent arteriolopathy [6], glomerular hypertrophy [7], and
interstitial inflammation [5]. Renal renin expression is
increased, and angiotensin-converting enzyme (ACE) in-
hibition ameliorates the kidney damage [6]. These ob-
servations raise the possibility of a uric acid–induced
nephropathy, and implicate activation of the intrarenal
renin-angiotensin system (RAS) as a mediator of uric
acid–induced nephropathy.
At the present time, there is no readily available means
of directly assessing intrarenal RAS activity in humans.
We have employed the renal vascular response to infused
angiotensin II (Ang II) as an indirect measure of activity
of the intrarenal vascular RAS [8]. Multiple lines of ev-
idence indicate that the response is inversely correlated
with endogenous RAS activity [9–12]. In light of the ani-
mal data suggesting that uric acid activates the intrarenal
RAS, we examined whether the serum uric acid concen-
tration predicts the renal vascular response to Ang II in
humans.
METHODS
Subjects and protocol
Subjects in this report were studied by the international
HyperPath (Hypertensive Pathotype) group. Included in
this report are a total 249 Caucasian and African Amer-
ican subjects who completed renal plasma flow (RPF)
studies in high salt balance and had the serum uric acid
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Table 1. Characteristics of subjects
All subjects Normotensives Hypertensives P valuea
Number 249 80 169
Age years 45.0 ± 10 37.7 ± 11 48.4 ± 7.4 <0.001
Gender female % 45 60 38 0.001
Race black % 11 18 9 0.05
Hypertension status HTN % 68 NA NA NA
Body mass index kg/m2 28.0 ± 4.4 25.9 ± 5.1 28.9 ± 3.7 <0.001
Systolic blood pressure mm Hg 132 + 23 110 + 13 142 + 19 <0.001
Diastolic blood pressure mm Hg 79.6 ± 13 66.4 ± 8.6 85.4 ± 10 <0.001
Fasting serum glucose mg/dL 87.7 ± 22 86.4 ± 25 88.2 ± 21 0.57
Fasting serum insulin uU/mL 11.3 ± 8.5 10.6 ± 6.3 11.7 ± 9.3 0.27
Serum total cholesterol mg/dL 184 ± 34 168 ± 32 191 ± 33 <0.001
Serum triglycerides mg/dL 162 ± 89 124 ± 84 176 ± 87 <0.001
Serum HDL mg/dL 42 ± 12 45 ± 13 41 ± 11 0.05
Serum uric acid mg/dL 5.4 ± 1.6 4.6 ± 1.6 5.8 ± 1.5 <0.001
PRA ng Ang I/mL/sec 0.49 ± 0.50 0.47 ± 0.43 0.49 ± 0.55 0.78
Creatinine clearance mL/min 107 ± 34 108 ± 30 107 ± 36 0.79
24 hour urine sodium mmol 240 ± 64 235 ± 65 243 ± 64 0.36
Basal RPF mL/min/1.73 m2 530 ± 109 591 ± 100 501 ± 102 <0.001
Abbreviations are: RPF, renal plasma flow; HTN, hypertension; PRA, plasma renin activity; HDL, high density lipoprotein. aP values for hypertensives vs.
normotensives.
Continuous values reported as mean ± SD, discrete as percentile.
concentration measured. We performed this analysis on
subjects studied during high sodium balance because of
the greater range of responsiveness during high sodium
balance [10] allows for easier detection of interindivid-
ual differences. Subjects were studied at the General
Clinical Research Centers (GCRCs) of the Brigham and
Women’s Hospital in Boston (N = 90), the University
of Utah Medical Center in Salt Lake City (N = 133),
or the Vanderbilt University Hospital (N = 26). The In-
stitutional Review Board of each center approved the
study, and all subjects gave written informed consent be-
fore enrollment, as described previously [13]. Protocols
were carefully standardized at each site through start-up
and periodic visits between clinic sites, regular conference
calls, and use of common written protocols and clinical
data collection forms. All assays were performed at a cen-
tral laboratory. Renal vascular responsiveness in a subset
of these subjects has been reported, but the analyses re-
lating it to uric acid are novel.
Of the 249 subjects, there were 152 with no other sibling
included, 94 from sibling pairs, and 3 from a trio. The clin-
ical and biologic characteristics of these subjects are in-
dicated in Table 1. The mean age of the subjects was 45 ±
10 years, 45% were female, 11% were black, and 68%
were hypertensive. The mean serum uric acid concentra-
tion was 5.4 mg/dL (range 1.7 to 10.0 mg/dL) (normal <
7.8 mg/dL in our laboratory). No study subject was taking
allopurinol.
Hypertension was defined as a diastolic blood pressure
of ≥100 mm Hg off medication, or ≥90 mm Hg while tak-
ing ≥ one medications, or treatment with ≥ two medica-
tions. Siblings had to have a diastolic blood pressure of
≥90 mm Hg off medication on ≥ three occasions or di-
astolic blood pressure of ≥80 mm Hg on one antihyper-
tensive medication on ≥ three occasions. In addition to
having a blood pressure <140/90 mm Hg, normotensives
did not have a first-degree relative with hypertension on-
set before 60 years of age. All subjects had a screening
history and physical and laboratory examination. Exclu-
sion criteria included diabetes mellitus, renal insufficiency
(serum creatinine >1.5 mg/dL), secondary forms of
hypertension (based on history, physical examination,
multichannel serum chemistry screening, and further
evaluation when indicated), or any other significant med-
ical problem. ACE inhibitors and angiotensin receptor
blockers were discontinued 3 months before study; all
other antihypertensive medications were stopped for at
least 2 weeks.
All subjects consumed a high salt diet (200 mmol
sodium) for 3 to 7 days prior to study. High sodium bal-
ance was defined by urinary excretion of ≥150 mmol
sodium/24 hours. Subjects were admitted to a metabolic
ward the night before studies. Effective RPF [as para-
aminohippuric acid (PAH) clearance] was calculated
from steady-state plasma PAH concentrations as previ-
ously described [13, 14]. Effective RPF was normalized
to a body surface area (BSA) of 1.73 m2 by the equa-
tion BSA = W0.452 × H0.0725 × 0.007184, where BSA is
in square meters, H is height in centimeters, and W is
weight in kilograms. Ang II was infused at 3 ng/kg/min
for 55 minutes on the study day. The RPF response to
Ang II was calculated by subtracting the post-Ang II PAH
clearance from the pre-Ang II PAH clearance. Diastolic
blood pressure was determined as the mean of three con-
secutive readings (by Dinamap) separated by 5 minutes,
each measured at bed rest on the morning of the study.
Creatinine clearance (mL/min) was calculated as [(urine
creatinine (mg/dL)/serum creatinine (mg/dL)] ∗ [urine
volume (mL)/time (hour) ∗ 60]. Details of all laboratory
assays have been described previously [13, 14]. Uric acid,
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drawn at the screening visit, was measured by a com-
mercially available assay (Olympus, Melville, NY, USA).
Serum glucose, serum insulin, lipid profile and plasma
renin activity (PRA) were measured fasting and supine.
Statistical analysis
Statistical analysis was performed with STATA ver-
sion 8.0. Subjects’ characteristics are expressed as means
and SD values for continuous variables and percent-
ages for discrete variables. Pearson or Spearman correla-
tions were generated for parametric and nonparametric
variables, respectively, with statistical significance deter-
mined by univariate regression analysis. All regression
analyses were clustered by family to account for non-
independence of related subjects. Hierarchical multivari-
able linear regression was used to determine if the serum
uric acid level is an independent predictor of the RPF re-
sponse to Ang II; forward and backward stepping yielded
the same result. All variables not included in the final
model were tested for confounding; if a variable changed
the effect estimate of uric acid by ≥20%, it was in-
cluded in the final model. Variables considered were age,
gender, race, hypertension status, systolic and diastolic
blood pressure, body mass index (BMI), serum glucose,
serum insulin, serum total cholesterol, serum triglyc-
erides, serum high-density lipoprotein (HDL) choles-
terol, PRA, creatinine clearance, and 24-hour urinary
sodium excretion. Dummy variables were used for gen-
der, race, hypertension status, and site to generate inter-
action terms. Diagnostic tests of leverage and influence
were used to evaluate the validity of the model.
RESULTS
Among all subjects, the mean renal plasma flow re-
sponse to Ang II was 104 ± 50 mL/min/1.73 m2. Figure 1
demonstrates that the mean RPF response to Ang II
decreases significantly by quartile serum uric acid con-
centration (P < 0.001). In univariate analysis, basal RPF
was the strongest correlate of this response (r = 0.67,
P < 0.001) (Table 2). Age, BMI, systolic blood pressure,
diastolic blood pressure, and serum triglycerides also
negatively correlated with the RPF response to Ang II.
Hypertensives had a lesser response than normotensives
(93 vs. 127 mL/min/1.73 m2). Women had a greater re-
sponse than men (112 vs. 97 mL/min/1.73 m2) (P = 0.02).
The serum uric acid concentration also correlated with
many baseline characteristics (Table 2). Basal RPF was
inversely correlated with serum uric acid concentration
(r =−0.30, P < 0.001) (Fig. 2). Hypertensives had a higher
serum uric acid concentration then normotensives (5.8 vs.
4.6 mg/dL) (P < 0.001), while women had a lower serum
uric acid concentration then men (4.6 vs. 6.0 mg/dL) (P <
0.001). BMI, systolic blood pressure, diastolic blood pres-
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Fig. 1. The renal plasma flow (RPF) response to angiotensin II (Ang
II) decreases with increasing quartile of uric acid. Bars represent mean
response per quartile, error bars are± standard error. Groups compared
by analysis of variance (ANOVA). Labeled are the mean and range of
serum uric acid concentration for each quartile.
sure, age, serum triglycerides, and serum insulin were pos-
itively correlated while serum HDL correlated negatively
with the serum uric acid concentration.
We analyzed to what extent the variation in serum uric
acid concentration could be predicted by baseline char-
acteristics. A regression model including basal RPF and
serum insulin explained 11% of the variation in the serum
uric acid. A regression model expanded to include all
characteristics that correlated with the serum uric acid
(P value for correlation < 0.10) explained 34% of the
variation serum uric acid concentration.
To examine possible confounding of including both
normotensives and hypertensives in the analysis, we in-
vestigated if the relationship between serum uric acid
concentration and the RPF response to Ang II differed
between normotensives and hypertensives. As seen in
Table 1, hypertensives were older, more frequently male,
heavier, had a higher serum uric acid concentration,
higher systolic blood pressure and diastolic blood pres-
sure, and lower basal RPF. Despite these differences, in
univariate analysis the correlation and slope of the rela-
tionship between the serum uric acid level and the RPF
response to Ang II were almost identical in normoten-
sives (r = −0.26, b = −8.2, P = 0.01) and hypertensives
(r = −0.26, b = −8.3, P < 0.001). There was not a signif-
icant interaction between serum uric acid concentration
and hypertension status (P = 0.78). Uric acid concentra-
tion independently predicted blunting of the renal vas-
cular response to Ang II [b = −5.3 (−8.1; −2.4), P <
0.001] (Table 3). Baseline RPF (b = 0.28, P < 0.001)
was the only other independent predictor. Age, gen-
der, race, hypertension status, systolic and diastolic blood
pressure, BMI, serum glucose, serum insulin, serum total
cholesterol, serum triglycerides, serum HDL cholesterol,
PRA, creatinine clearance, and 24-hour urinary sodium
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Table 2. Correlations with the renal plasma flow (RPF) response to angiotensin II (Ang II) and the serum uric acid concentration
RPF response to Ang II Serum uric acid
r P value r P value
Basal RPF mL/min 1.73 m2 0.67 <0.001 −0.30 <0.001
Serum uric acid mg/dL −0.37 <0.001 NA NA
Age years −0.35 <0.001 0.23 <0.001
Body mass index kg/m2 −0.36 <0.001 0.42 <0.001
Hypertension status HTN −34.9 <0.001 1.2 <0.001
Systolic blood pressure mm Hg −.034 <0.001 0.26 <0.001
Diastolic blood pressure mm Hg −0.33 <0.001 0.27 <0.001
Serum triglycerides mg/dL −0.32 <0.001 0.47 <0.001
Serum HDL mg/dL 0.18 0.008 0.40 <0.001
Gender female 14.9 0.02 1.44 <0.001
Serum insulin uU/mL −0.13 0.07 0.27 0.002
Race black 16.7 0.08 0.71 0.04
Serum total cholesterol mg/dL −0.12 0.09 0.23 0.004
PRA ng Ang I/mL/sec −0.03 0.25 0.13 0.33
Creatinine clearance mL/min −0.06 0.31 0.11 0.05
24-hour urine sodium mmol −0.05 0.4 0.09 0.14
Serum glucose mg/dL −0.07 0.69 0.09 0.99
Abbreviations are: HTN, hypertension; PRA, plasma renin activity; HDL, high-density lipoprotein.
Pearson or Spearman correlations presented. For discrete variables, mean difference is reported. Statistical significance was determined by univariate linear regression.
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Fig. 2. Serum uric acid is negatively correlated with baseline renal
plasma flow (RPF) (r = −0.30, P < 0.001).
excretion were not independently associated with the
RPF response to Ang II. A multivariable model sub-
stituting basal renal vascular resistance index (diastolic
blood pressure/RPF) for basal RPF yielded a similar
effect estimate for serum uric acid (b = −5.3, P =
0.001). No variable had a significant confounding ef-
fect. Site did not influence the relationship between
serum uric acid level and the RPF to Ang II. Di-
agnostics did not reveal any observation with signif-
icant leverage or influence. The interaction term for
race and serum uric acid was not significant (P =
0.65).
We explored in greater depth whether gender had an
effect on the relationship between serum uric acid con-
centration and the RPF response to Ang II. Figure 3
presents the relationship between the serum uric acid
concentration and the RPF to Ang II in men and women.
Table 3. Final model for predicting the renal plasma flow (RPF)
response to angiotensin II (Ang II)
Regression
coefficient 95% CI P value
Basal RPF 0.29 [0.24; 0.33] <0.001
mL/min/1.73 m2
Uric acid mg/dL −5.3 [−8.1; −2.4] <0.001
Multivariable linear regression determined independent predictors of the RPF
response to Ang II. Variables considered were age, gender, race, hypertension
status, systolic and diastolic blood pressure, body mass index, creatinine
clearance, serum uric acid, basal renal plasma flow, 24-hour urinary sodium
excretion, seurm glucose, serum insulin, serum cholesterol, serum triglycerides,
serum high-density lipoprotein (HDL) and plasma renin activity.
As described earlier, women had a lower serum uric acid
concentration and a greater RPF response to Ang II. Pre-
diction lines of the RPF response to Ang II among men
and women are superimposed. In accord with this, the in-
teraction term between gender and serum uric acid con-
centration was not significant (P = 0.93).
DISCUSSION
Whether uric acid contributes directly to hyperten-
sion and renal disease in humans remains unresolved. A
recently developed animal model of hyperuricemia has
provided compelling data suggesting that uric acid can
contribute to hypertension and nephropathy [15]. The
experimental model employs oxonic acid, an inhibitor of
uricase, causing elevation of the serum uric acid concen-
tration but not sufficiently so as to cause crystal forma-
tion. The oxonic acid–treated rat develops hypertension
that corrects with hypouricemic therapy [5]. Independent
of the rise in blood pressure, afferent arteriolopathy [6]
and glomerular hypertrophy [7] are seen. Additionally,
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Fig. 3. The observed and predicted renal plasma flow (RPF) response
to angiotensin II (Ang II) plotted against the serum uric acid level in
women and men. Women tend to have a higher serum uric acid level and
a higher RPF to Ang II than men. The prediction lines are overlapping,
indicating that the relationship between the RPF response to Ang II
and the serum uric acid level is essentially identical in men and women.
the kidney exhibits a pattern of interstitial injury consis-
tent with exposure to Ang II [5, 16]. Renin is increased in
the kidney of the hyperuricemic rat, and ACE inhibition
ameliorates the renal injury [6]. These studies suggest the
existence of a uric acid–mediated nephropathy, and impli-
cate uric acid–induced activation of the intrarenal RAS
as a key mediator of the renal damage. The mechanism
by which uric acid increases RAS activity is not clear.
We have used the renal vasoconstrictor response to
exogenous Ang II as an indirect measure of intrarenal
RAS activation in humans [17]. Multiple lines of evi-
dence indicate that this response is inversely correlated
with endogenous RAS activity [9–12]. The response is
blunted during low sodium balance when endogenous
RAS activity is greater [10]. The response to Ang II dur-
ing low sodium balance is inversely correlated with the
vasodilator response to an ACE inhibitor[12]. ACE inhi-
bition enhances renal vascular responsiveness to Ang II
[18]. More recently we have found that variation within
the angiotensinogen gene associated with increased an-
giotensinogen expression predicts blunted renal vascular
responsiveness to exogenous Ang II [13, 19].
In light of the work in experimental hyperuricemia,
we examined serum uric acid in our subjects who have
received intravenous Ang II under carefully controlled
conditions. We found that the serum uric acid concentra-
tion independently predicted blunted renal vascular re-
sponsiveness to Ang II. Our result is consistent with the
observation in animals that hyperuricemia is associated
with activation of the intrarenal RAS.
Studies in humans have largely concluded that hype-
ruricemia reflects and does not contribute to renal dys-
function. In particular, elevation in serum uric acid has
been attributed to either renal vascular abnormalities [3]
or increased proximal tubule sodium resorption [4]. Hy-
perinsulinemia secondary to insulin resistance has been
suggested as a cause of increased proximal tubule urate
resorption [20, 21]. In our analysis the serum uric acid
concentration predicted the RPF response to Ang II inde-
pendently of both baseline RPF and serum insulin levels.
We found it revealing that basal RPF and serum insulin
levels accounted for only 11% of the variation in serum
uric acid concentration, suggesting that these factors do
not have a dominant role in uric acid homeostasis.
We examined specifically if gender based differences
may have accounted for our observations, as women
had lower serum uric acid concentrations and have been
found to have increased renal responsiveness to exoge-
nous Ang II [22, 23]. We found that the relationship be-
tween the serum uric acid concentration and the RPF
response to Ang II was not different in men and women.
The possibility that uric acid is associated with in-
trarenal RAS activation in humans may provide insight
into several observations that have been made, given that
Ang II is strongly implicated in the pathogenesis of hy-
pertension and nephropathy [24]. Hyperuricemia is an
independent predictor of the development of hyperten-
sion [25] and is highly specific for essential hypertension
among pediatric patients [26]. Uric acid independently
predicts risk for renal insufficiency among subjects with
normal renal function [27] and the progression of IgA
nephropathy [28].
It is interesting to speculate that activation of the in-
trarenal RAS might not be the primary mechanism re-
sponsible for what we have found. Changes in nitric oxide
synthase (NOS) activity can influence vascular respon-
siveness to Ang II [5], and decreased NOS expression was
observed in the hyperuricemic rat [29]. Also, it is possible
that an association of uric acid with the intrarenal RAS
could be driven by Ang II decreasing uric acid clearance
[30] or increasing xanthine oxidase activity [32]. How-
ever, pharmacologic interruption of Ang II activity is not
significantly hypouricemic [33], suggesting that RAS ac-
tivation is not a major determinant of hyperuricemia.
This analysis is exploratory in nature. While back-
ground studies suggest uric acid activates the intrarenal
RAS, our study cannot determine causation. The serum
uric acid concentration was determined at the screening
visit and not on the study day, though we feel this would
likely bias our result toward the null hypothesis. We could
not test if the relationship of serum uric acid to blunted
renal vascular responsiveness is specific to Ang II. While
in our analysis we tested for confounding, interaction,
leverage and influence, we acknowledge the assumptions
and limitations of multivariable regression as an analytic
tool. We have tested the renal vascular response to Ang II
and therefore only have an indication of intrarenal vas-
cular RAS activity. Finally, although we have included
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baseline RPF as a predictor in our multivariable model,
we acknowledge that we cannot totally dissociate the
serum uric acid level from renal hemodynamics. The
strengths of this study are its biologic plausibility, large
sample size, accounting for relevant confounders, and
carefully controlled experimental conditions.
We have found that the serum uric acid level predicts
blunted renal vascular responsiveness to Ang II in hu-
mans. These data suggest that uric acid is associated with
an activated intrarenal RAS and therefore may provide
insight into the relationship between the serum uric acid
level and the risk for hypertension and nephropathy. Fur-
ther investigation into the relationship between uric acid
and the intrarenal RAS is warranted.
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